|Home | About | Journals | Submit | Contact Us | Français|
Addiction occurs through repeated abuse of drugs that progressively reduce behavioral control and cognitive flexibility while increasing limbic negative emotion. Recent discoveries indicate neuroimmune signaling underlies addiction and co-morbid depression. Low threshold microglia undergo progressive stages of innate immune activation involving astrocytes and neurons with repeated drug abuse, stress, and/or cell damage signals. Increased brain NF-κB transcription of proinflammatory chemokines, cytokines, oxidases, proteases, TLR and other genes create loops amplifying NF-κB transcription and innate immune target gene expression. Human post-mortem alcoholic brain has increased NF-κB and NF-κB target gene message, increased microglial markers and chemokine-MCP1. Polymorphisms of human NF-κB1 and other innate immune genes contribute to genetic risk for alcoholism. Animal transgenic and genetic studies link NF-κB innate immune gene expression to alcohol drinking. Human drug addicts show deficits in behavioral flexibility modeled pre-clinically using reversal learning. Binge alcohol, chronic cocaine, and lesions link addiction neurobiology to frontal cortex, neuroimmune signaling and loss of behavioral flexibility. Addiction also involves increasing limbic negative emotion and depression-like behavior that is reflected in hippocampal neurogenesis. Innate immune activation parallels loss of neurogenesis and increased depression-like behavior. Protection against loss of neurogenesis and negative affect by anti-oxidant, anti-inflammatory, anti-depressant, opiate antagonist and abstinence from ethanol dependence link limbic affect to changes in innate immune signaling. The hypothesis that innate immune gene induction underlies addiction and affective disorders creates new targets for therapy.
Chronic use of alcohol stimulants and/or opiates lead to progressive changes in the brain and behavior, often leading good, smart and sane people to do bad, stupid and crazy things that hurt themselves and others. The continued and often escalating horrific, unpleasant, awful events associated with increasing drug use resulting in addiction are well known. Medical emergencies due to accidents, drug overdoses, violent desperate, impulsive illegal behavior, physical injuries criminal justice problems (Li 2008; Gilson 2010) and other negative consequences associate with drug addiction (Hingson et al. 2009; Mendelson et al. 1986). Alcohol or opiate dependence was first defined by neurological and physiological withdrawal symptoms including hyperexcitability, fever, anxiety and feelings of sickness. However, modern medicine focuses psychological dependence that causes loss of behavioral control (Kalivas and O'Brien 2008; Koob and Volkow 2010). Addiction can be defined as a primary, chronic, neurobiological disease, with genetic, psychosocial, and environmental factors influencing its development and manifestations. It is characterized by behaviors that include impaired control over drug use, compulsive use, continued use despite harm, and craving (Ries et al. 2009; Volkow et al. 2011). Substance Dependence, a Psychiatric diagnosis is defined as “repeated use of alcohol or other drugs despite problems related to use of the substance (O'Brien 2008). Critical to these medical diagnoses of severe addiction is the continued use of drugs despite the harm to the individual, family and community due to the loss of ability to alter behavior in spite of problems. This review will describe changes in the neurobiology of the brain related to severe addiction.
The loss of behavioral control that underlies addiction has at least 2 components, decreased frontal cortical regulation of attention and cognitive flexibility and increased limbic fear-negative feelings (Fig. 1). The frontal lobes of brain are involved in decision making and other executive functions such as motivation, planning, goal setting and inhibition of impulses. Frontal lobe functions also predict future consequences, choose between good and bad actions (or better and best), override and suppress unacceptable social responses, and determine similarities and differences between things or events. The frontal lobes also play an important part in retaining long term emotional memories and adjusting emotions to fit socially acceptable norms important for individual integration into society. Frontal behavioral control mechanisms block impulsive mistakes and predict future rewards (Schoenbaum and Shaham 2008). Loss of these functions is a key element of the neurobiology of addiction and substance dependence (Fig. 1).
The limbic system supports a variety of functions particularly emotion, fear or elation, needs and urgency, long term memory, and olfaction. Addiction induced negative affect, mood and fear are associated with amygdale and hippocampus human temporal lobe structures (Fig. 1). Limbic urgency helps drive impulsive behaviors (Crews and Boettiger 2009). Across drugs of addition, the progression from abuse to addiction involves increasing drug wanting, negative emotional urgency and decreasing behavioral control (Jentsch and Taylor 1999; Robinson and Berridge 2003). Thus, the neurobiology of addiction involves dysfunctional frontal cortex behavioral control as well as exaggerated limbic urgency (Fig. 1). This review will present the hypothesis that innate immune gene induction in frontal cortex blunts behavioral control, whereas it amplifies limbic negative affect and bad feelings.
Neuroimmune signaling contributes to enteric, sensory, endocrine hypothalamic-adrenal (HPA) responses to external and internal environmental factors. Monocytes and brain microglia, are sensitive key cells involved in innate immune signaling. Neuroimmune signaling through microglia and other monocyte-like cells integrates sensory and endocrine enteric responses with brain. Microglia are unique monocyte-macrophage-like cells that share multiple stages of activation reflected morphologically and in gene expression (Hingson et al. 2009; Graeber 2010). Microglia are formed embryonically and migrate to fetal brain early in development creating a unique self-renewing monocyte-like cell that is maintained by self-renewal. Microglia and vascular monocyte-macrophages are the primary innate immune cells in brain (Ransohoff and Cardona 2010). Healthy brain contains ramified “resting” microglia known to survey brain and regulate synapses (Graeber 2010). Microglia have a low threshold of activation with initial states secreting signaling molecules, increasing expression of Major Histocompatibility Complex (MHC) proteins and Toll-like receptor proteins (TLR), key proteins involved in innate immune amplification. Morphological activation states show cellular enlargement, increased cell matrix and adhesion protein expression and progressive induction of other specific genes. Efforts to establish subtypes of microglia have designated M1 and M2 states as proinflammatory and trophic respectively, although additional subtypes continually emerge (Colton and Wilcock 2010). Activated enlarged morphology is often associated with secretion of chemokines regulating cellular movement, particularly to sites of tissue damage, that progress to proinflammatory-oxidative activation that includes protease secretion. Highly activated microglia progress to mitosis, proliferation and phagocyte oxidative bursts that oxidize and engulf waste (Graeber 2010). “Amoeboid” phagocytic rounded macrophage-like cell morphology is common in neurodegenerative diseases and senescence (Colton and Wilcock 2010). Microglia can also initiate trophic and other signals needed for healing (Crews et al. 2006). Microglia are important components of brain that regulate brain function in complex ways not fully understood. Emerging studies suggest brain suppress microglial activation promoting a trophic “resting” state (Liu et al.). Stress, ethanol, other addictive drugs as well as sensory and hormonal signals activate monocytes and microglia. Cycles of stimuli lead to microglial adaptive conditioning (Shpargel et al. 2008). Interestingly, microglial dysfunction has been discovered to contribute to obsessive-compulsive behaviors (Greer and Capecchi 2002), consistent with microglia contributing to the neurobiology of addiction. Thus, microglia are sensitive to addictive drugs and stress, that lead to progressive adaptation that could alter neurobiology and behavior through innate immune gene induction.
Stress, ethanol, other addictive drugs, as well as sensory and hormonal signals, activate an oxidation sensitive transcription factor, NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells), that is highly expressed in monocytes and microglia. Monocytes and microglia express high levels of the transcription factor NF-κB as well as low levels of innate immune genes under normal conditions. Although NF-κB is found in most cells, it is the key transcription factor involved in induction of innate immune genes in microglia and other monocyte-like cells. Stimuli such as stress, cytokines, oxidative free radicals, ultraviolet irradiation, bacterial or viral antigens, and many other signaling molecules increase NF-κB-DNA binding and transcription of many genes particularly chemokines, cytokines, oxidases and proteases (Fig. 2). We find that ethanol increases NF-κB–DNA binding in brain in-vivo (Crews et al. 2006) or in-vitro in hippocampal-entorhinal cortex (HEC) brain slice cultures (Zou and Crews 2006). Our studies and others indicate that ethanol increases transcription of NF-κB target genes including the chemokine MCP-1 (CCL2), the proinflammatory cytokines, TNFα, IL-1β, and IL6, the proinflammatory oxidases, iNOS (Zou and Crews 2010), COX (Knapp and Crews 1999), NOX (Qin et al. 2008) and proteases TACE and tPA (Zou and Crews 2010) (Fig. 2). Similarly stress increases brain NF-κB activation (Madrigal et al. 2001), cytokines, prostaglandin E2 and COX-2 levels (Madrigal et al. 2003) in part due to reversal of acute glucocorticoid anti-inflammatory responses to pro-inflammatory NF-κB activation in frontal cortex (Munhoz et al. 2010). Stress and drug abuse cycles promote addiction and elevate glucocorticoids (Armario 2010), likely contributing to activation of brain NF-κB transcription of innate immune genes. Methamphetamine shows similar persistent innate immune activation to ethanol in mice and humans (Loftis et al. 2010). Thus, the synergy of stress-drug abuse cycles leading to progressive loss of behavioral control and addiction are consistent with persistent, progressive brain innate immune gene induction.
Activation of the NF-κB spreads through positive loops (Fig. 2) increasing activation within and across glia and neurons (Zou and Crews 2010). Autocrine signaling involves secretion of signaling molecules that act on the same cells receptors to amplify activation of that cell, whereas paracrine signaling involves release of signals that activate cells nearby spreading the signal across cells. For example, reactive oxygen species (ROS) can increase NF-κB transcription of TNFα and TACE, the TNFα activating protease, as well as the TNFR1 receptor. Released TNFα stimulates NF-κB transcription through TNFR1 amplifying the signal in that cell and adjacent cells promoting TNFα induction (Fig. 2). Stress and drugs acutely signal through brain NF-κB. For example, restraint stress in rats induces brain NF-κB target genes TACE and TNFα mRNA within 30 minutes, and free mature brain TNFα within 1 hour (Madrigal et al. 2002). Similarly an acute dose of ethanol activates NF-κB in brain within 30 minutes (Ward et al. 1996). Although NF-κB is expressed in most cells, in brain NF-κB is transcriptionally active primarily in glia (Mao et al. 2009), although, confusion regarding neuronal NF-κB is commonly found in the literature (Massa et al. 2006). Activation of NF-κB acutely leads to paracrine and autocrine amplification during repeated drug abuse and/or stressful events that create loops of NF-κB activation amplifying innate immune gene induction (Fig. 2). The loops of NF-κB activation lead to persistent increases in oxidative free radicals from oxidases, increased TLR expression with increased formation of endogenous TRL agonists, and chemokine-cytokine receptor upregulation (Qin et al. 2008; Zou and Crews 2010). Ethanol and stress activate microglia to secrete NF-κB target genes leading to mild activated morphology with repeated cycles progressively increasing innate immune gene induction. Maximally activated phagocytic oxidative burst macrophage-like microglial activation occurs with severe neurodegeneration, but is rare in addiction without severe degeneration (He and Crews 2008; Qin et al. 2008). These studies indicate that repeated drug abuse and stress lead to loops of NF-κB transcription of innate immune genes that mimic the progressive and persistent changes in behavior associated with the transition from drug experimentation to addiction.
A number of studies suggest astrocytes and microglia are activated in addiction. Using both in vitro and in vivo models through a series of elegant studies Guerri's laboratory has clearly established that chronic ethanol treatment induces astroglial activation and astrogliosis in brain as indicated by marked upregulation of GFAP immunoreactivity within hypertrophic astrocytes, (Wilhelmsson et al. 2006; Chvatal et al. 2007; Gomez-Pinedo et al. 2008). TLR are pattern recognition receptors that activate NF-κB transcription. TLR and interleukin-1 receptors are expressed on microglia and other cells during innate immune activation contributing to amplification of signaling. Recently TLR4 was discovered to contribute to persistent innate immune gene induction and neurodegeneration by ethanol (Alfonso-Loeches et al. 2010). Guerri's studies indicate that chronic ethanol upregulation and activation of TLR4-MyD88-glial NF-κB signaling contributes to alcohol induced neurodegeneration. Acute alcohol activates TLR4 signaling to NF-κB as well as increasing expression of TLR4 (Alfonso-Loeches et al. 2010). These studies are consistent with ethanol induction of innate immune genes altering behavior and causing neurodegeneration related to addiction. Indomethacin, an anti-inflammatory drug, reduces chronic ethanol induction of brain innate immune genes, particularly in astrocytes, as well as neuronal markers of cell death and addiction-like behavioral dysfunction (Pascual et al. 2007) consistent with innate immune gene induction driving the neurobiology of addiction. Innate immune activation from oxidized phospholipids (Yang et al. 2010), and/or release of damage associated molecular pattern (DAMP) danger sensing molecules, such as high-mobility group box 1 (HMGB1) (Garg et al. 2010), that activate TLR and other signals are likely contributors to innate immune gene induction (Huang et al. 2010)(Fig. 2). Although loops of NF-κB activation are best established in models of alcoholism, all addictive drugs activate NF-κB transcription with the development of addiction (Russo et al. 2009; Loftis et al. 2010). These studies support innate immune gene induction in glia as important contributors to the neurobiology of addiction.
Anxiety and the bad feelings of negative affect are associated with increased drug craving as a key component of addiction (Breese et al. 2005; Koob and Volkow 2010). Breese' laboratory models addiction with repeated cycles of ethanol consumption and/or stress that progressively amplify anxiety and negative affect consistent with the cycles of stress and drug abuse known to promote addiction. Interestingly, brain injections of innate immune inducing molecules, e.g. the chemokine MCP-1, the cytokine TNFα, or the TLR4 agonist, lipopolysaccaride an innate immune inducer, progressively increase addiction-like anxiety substituting for an episode of stress or drug abuse (Breese et al. 2008). Cycles of stress and/or drug abuse cause progressive addiction-like anxiety and are known to induce innate immune genes in brain. The discovery that innate immune molecules injected into brain substitute for stress and/or drug abuse cycles promoting addiction-like anxiety, supports the role innate immune genes in driving the neurocircuitry and neurobiology that result in addiction-like behavior.
Opiates are known to be addicting drugs and have endogenous opiate receptors that contribute to the neurobiology of addiction (Koob and Volkow 2010). Opiate antagonists are used to treat both alcohol and opiate addiction. Interestingly, opiate antagonists block innate immune gene induction through a different novel mechanism that might contribute to the reversal of addiction-like behavior. LPS, endotoxin, induces large innate immune responses that are blocked by opiate antagonists (Liu et al. 2000) and protect dopamine neurons through inhibition of microglial innate immune activation and reduced NOX formation of ROS (Liu et al. 2000; Qin et al. 2005), independent of their opiate antagonist actions. Other studies find opiate antagonists block TLR4 activation of innate immune transcription, a site of action in innate immune loops (Fig. 2) (Gerald Frank 2011; Hutchinson 2011). Thus, opiate antagonist addiction therapy may be related to inhibition of innate immune responses.
Insight into the neurobiology of addiction can be gained from studies of post-mortem human brain. We found monocyte chemoattractant protein 1 (MCP-1, CCL2), a key innate immune chemokine, increased several fold in multiple regions of post-mortem alcoholic brain compared to age matched moderate drinking controls (Fig. 3) (He and Crews 2008). MCP-1 protein levels from alcoholic and control human brains indicated increased MCP-1 in ventral tegmental area (VTA), substantia nigra (SN), hippocampus and amygdala of alcoholic brains. We also found increased levels of microglial markers across alcoholic brain (He and Crews 2008). Chronic alcohol treatment of mice causes a similar persistent increase in brain MCP-1 (Fig. 3) (Qin et al. 2008). Interestingly, ethanol treatment of rat hippocampal brain slice cultures also increase MCP-1 and other innate immune genes (Fig. 3) (Zou and Crews 2010). These studies indicate that ethanol induces MCP-1 in rats and mice creating neurobiological changes found in human addicted brain (Fig. 3). Similarly, human methamphetamine addicts and mice treated with methamphetamine show persistent increases in innate immune proteins (Loftis et al. 2010). Increased protein levels are also reflected by increased mRNA. Gene arrays following mRNA expression in post-mortem human alcoholic brain find increased NF-κB and target gene expression. Okvist (2007) found chronic alcoholic brain to contain increased NF-κB nuclear binding p50 subunits with 479 NF-κB target genes upregulated in the frontal cortex. Another post-mortem alcoholic human gene expression analysis (Liu et al. 2006) found increases in innate immune cell adhesion and extracellular membrane (ECM) components. Thus, studies of post-mortem human alcoholic brain are consistent with increased innate immune gene expression in addicted brain.
Genetics contribute to risk of addiction with alcoholism being the most studied and experimentally established addiction with a significant genetic risk. Genes explain about 50% of the risk of alcohol addiction (Schuckit 2009). Interestingly, polymorphisms of Cyp2E1, an enzyme that metabolizes ethanol is associated with risk for alcoholism (Webb et al. 2010). In vivo, Cyp2E1 is highly expressed in monocyte-like cells where ethanol is immediately sensed through osmotic and Cyp2E1 metabolism. Cyp2E1 metabolism of ethanol increases ROS that activate proinflammatory NF-κB responses (Cao et al. 2005) (Fig. 2). Other human studies have found a direct link of NF-κB p50 to alcohol dependence (Flatscher-Bader et al. 2005; Okvist et al. 2007;Taylor et al. 2008). Polymorphisms in the precursor gene (NF-κB 1) of the NF-κB p50 subunit associate with risk for alcoholism (Taylor et al. 2008). Alleles of TNFα that increase expression have been linked to alcoholism and alcoholic liver disease (Pastor et al. 2000; Powell et al. 2000; Pastor et al. 2005). Alleles of IL-10 have also been linked to alcoholism (Pastor et al. 2000). Interestingly, in both cases alleles associated with alcoholism increase pro-inflammatory responses, e.g. alleles associated with alcoholism increase pro-inflammatory cytokine TNFα and decrease anti-inflammatory IL-10 secretion. Similarly polymorphisms, to the Interleukin-1 receptor antagonist and multiple other alleles of the IL-1 gene complex are associated with risk for alcoholism (Saiz et al. 2009). Thus, gene polymorphisms that alter innate immune NF-κB and NF-κB target gene expression are associated with genetic risk for human alcoholism consistent with increased brain innate immune gene expression contributing to the neurobiology of addiction.
Innate immune gene expression is known to alter behavior. The most serious side effect of treatment of cancer patients with proinflammatory interferon and interleukin is severe depression that must be treated with antidepressants. Multiple other studies have linked negative affect and depression to innate immune activation (Kelley 2011). Bacterial endotoxin (LPS) an effective inducer of innate immune genes causes sickness behavior and negative affect across multiple species. In rodents, models of depression-like behavior are linked to innate immune activation and in healthy humans LPS infusions reduce reward responses and increase depressed mood (Eisenberger et al. 2010). Increased negative affect is an important component of the neurobiology of addiction (Koob and Volkow 2010).
Drug consumption is also linked to innate immune gene expression. Addictionlike drinking behavior in rats and mice associates with increased NF-κB, its regulatory proteins and innate immune genes (Mulligan et al. 2006). Interestingly, microglobulin (β2M) an NF-κB target gene involved in microglial MHC immune signaling (Pahl 1999) shows the largest increase in high alcohol preferring brain transcriptomes (Mulligan et al. 2006). Innate immune gene induction in multiple mouse studies finds induction suppression through transgenic knock outs associates with increased drinking or decreased drinking respectively across strains of mice. These studies further support the role of these genes in regulating excessive addiction like drug consumption (Blednov et al. 2005; Blednov 2010). A single injection of LPS is able to produce a long-lasting increase in alcohol consumption (Blednov 2011) that corresponds to persistent increases in brain innate immune gene expression (Qin et al. 2007). These findings are consistent with innate immune gene expression driving addiction like behavior, both excessive consumption and the negative-affect, anxiety and depression-like behaviors of addiction.
Emotion or affect have an impact on health with positive affect or happiness associating with health and negative affect, bad feeling with illness. Psychiatric affective disorders cover a range of negative affect elements including anger, anxiety, melancholia, depression, major depressive disorder and substance use disorder. Drug addiction cues include a visceral emotional “gut” reaction, often one of uneasiness until the habit is satisfied. A variety of studies suggest that the extended amygdale, a neuroanatomic circuit including the amygdale, hippocampus, bed nucleus of the stria terminalis and the nucleus accumbens integrate brain arousal–stress systems producing negative emotional states that promote the development of addiction (Koob and Volkow 2010). Mood and negative affect are reflected in the co-morbidity of addiction and depression. About half of individuals with a lifetime history of alcoholism also have depression (Miller et al. 1996; Schuckit et al. 1997) and reversal of depression and alcohol dependence are linked (Mueller et al. 1994; Greenfield et al. 1998). Progressive drug-induced negative affect and depression-like behaviors are important components of addiction (Koob and Volkow 2010). The overlapping findings of increased innate immune gene expression in addiction and depression are consistent with a common molecular mechanism of addiction induced depression and endogenous depression.
A significant body of evidence supports the hypothesis that innate immune gene induction in brain causes negative affect and depression-like behavior (Raison et al. 2009). Patients with major depression have increased blood proinflammatory markers and antidepressant therapy is associated with decreases in markers. In addition to increased innate immune gene expression, human depression involves structural changes in hippocampus with multiple studies finding hippocampal volume is decreased in patients with depression (Videbech and Ravnkilde 2004). Other studies have associated loss of hippocampal neurogenesis, the formation of new neurons, with depression and hippocampal shrinkage. Interestingly, antidepressants increase hippocampal neurogenesis in models of depression and increase humans hippocampal volume during reversal of depression (Dranovsky and Hen 2006). Stress, multiple addictive drugs, innate immune genes and other factors that precipitate depression, reduce hippocampal neurogenesis (Tanapat et al. 2001; Malberg and Duman 2003; Gregus et al. 2005). Factors that reduce neurogenesis increase depression-like behavior (Johnson et al. 2006). Activation of NF-κB is necessary for stress induced inhibition of neurogenesis and induction of depression-like behavior (Koo and Duman 2008) as well as social defeat models of depression (Christoffel et al. 2011). Further, antidepressant efficacy in rodent behavioral models requires hippocampal neurogenesis (Santarelli et al. 2003). In animal studies, endotoxin induced increases in innate immune genes reduce neurogenesis and increase depression-like behavior (Kelley 2011). TLRs are necessary components of both ethanol neurotoxicity (Alfonso-Loeches et al. 2010) and innate immune induced depressive behavior and reduction of neurogenesis (Kelley 2011). TLR, glutamate hyperexcitability and endogenous TLR agonists lead to persistent increases in brain hyperexcitability (Maroso et al. 2010). We have found that chronic ethanol increases brain innate immune genes, reduces brain neurogenesis and increases depression-like behavior (Stevenson et al. 2009) (Fig. 4.) Ethanol induced loss of neurogenesis paralleled the onset of depression-like behavior with both reversed by anti-depressant treatment (Stevenson et al. 2009). Similarly stress induced IL-1β reduces neurogenesis causing depression like behavior (Koo and Duman 2008). Thus, neurogenesis reflects mood, with reduced neurogenesis associated with innate immune gene induction, drug induced negative affect and depression-like behavior. Interestingly, recovery from alcoholism is associated with improved mood and cognition, human brain enlargement and increased neurogenesis (Crews and Nixon 2009). Overall findings suggest adult hippocampal stem cells and neurogenesis provide an index of mood and negative affect that allow molecular studies on regulation of mood, both negative and positive (Crews and Nixon 2003; Koo et al. 2011) (Fig.4). These findings are consistent with drug induced depression sharing common mechanisms with endogenous depression as well as the negative affect of substance use disorder, e. g. addiction.
The frontal cortex is involved in attention, rule setting, decisions and behavioral control. It connects to multiple brain regions through excitatory glutamatergic neurons. Reciprocal connections to thalamus and limbic regions involve focal excitation that is disrupted by innate immune gene induction. In astrocytes, activation of NF-κB increasing expression of proinflammatory innate immune genes (Zou and Crews 2006; Pascual et al. 2007; Zou and Crews 2010) and reduces astrocyte glutamate transport (Zou and Crews 2005) causing an increase in extracellular glutamate increasing neuron excitiation and excitotoxicity (Zou and Crews 2006). Innate immune induced hyperexcitability due to loss of cortical glutamate transporters inactivates the frontal lobes contributing to the neurobiology of addiction (Crews et al. 2006). Other studies have indicated genetic factors linked to a hyperglutamate state to alcoholism (Spinagel, 2005) and ethanol induced NF-κB activation to increased extracellular glutamate (Ward et al. 2009). Innate immune gene induction causes hyperexcitability in the spinal cord related to neuropathic pain (Graeber 2010) and in the hippocampus related to seizures (Maroso et al. 2010). Hyperexcitability in the frontal cortex results in loss of cognitive flexibility creating addiction-like behavior (Gruber 2010). Kalivas' laboratory in elegant studies have established that cocaine and stimulant addiction are related to hyperglutamate states due to alterations in the cortical glutamate transporters, (Reissner and Kalivas 2010). These studies and others have suggested that anti-oxidants and other drugs that block innate immune gene cascades may provide new therapies for addiction.
Frontal cortical dysfunction is often investigated using reversal learning tasks. In reversal learning, expected outcomes are wrong requiring flexible behavior in response to outcomes that do not match those predicted by the preceding cues (Stalnaker et al. 2009). Reversal learning tasks in behavioral studies mimic the inability of drug addicted individuals to learn new healthy behaviors, when alcohol and other drugs have established strong associations. A frontal cortical signal is needed to indicate the value of decisions and is needed when new learning and/or behavior is necessary. We found that models of binge drinking induce persistent deficits in reversal learning in rats (Obernier et al. 2002) and in adult mice following a model of adolescent binge drinking (Coleman 2010). Other studies have found rats with previous experience either with self-administration of cocaine or with passive cocaine injections, are abnormally slow to learn reversals, even though they learn initial contingencies at a normal rate (Schoenbaum et al. 2004; Calu et al. 2007). Lesions of the frontal cortex cause reversal learning deficits in tasks similar to chronic drug abuse induced deficits (Schoenbaum et al. 2006). Studies of both human cocaine and alcohol addicts have found dysfunctional decision making in tasks involving delaying reward for more value and reversal learning tasks that probe cognitive flexibility and frontal lobe function (Bechara et al. 2002). The persistence of addiction, a chronic relapsing disorder, compares with the persistence in innate immune gene induction (Qin et al. 2007; Qin et al. 2008) and loss of behavioral flexibility.
Adolescence is an important developmental period when drug experimentation increases and behavioral control mechanisms mature. The frontal cortex develops during adolescence in parallel with the development of behavioral control (Ernst et al. 2009). The adolescent frontal cortex is uniquely sensitive to binge drinking neurotoxicity (Crews et al. 2000) and adolescent hippocampus uniquely sensitive to alcohol inhibition hippocampal of neurogenesis (Crews et al. 2006). Loss of frontal cortical function causes perseveration and repetition of previously learned behaviors due to failure to associate new information, e.g. negative consequences, into decision making. Models of adolescent binge drinking result in persistent reversal learning deficits (Coleman 2010) and persistent increases in proinflammatory innate immune gene expression and markers of neurodegeneration (Pascual et al. 2007). Anti-infammatory drugs protect against adolescent binge drinking brain damage models (Pascual et al. 2007) Initiation of drug experimentation during adolescence when frontal cortical behavioral control circuitry is developing increases vulnerability for life-long addiction (Crews et al. 2007). These studies suggest anti-inflammatory therapies may have value in reducing drug induced changes in neurobiology that contribute to addiction.
The neurobiology of addiction develops over a course of repeated drug abuse and/or stress. Changes in neurobiology underline altered mood and cognition related to increased limbic negative affect and loss of frontal cortical behavioral control. Drug abuse, stress and other factors increase NF-κB transcription of multiple proinflammatory genes that spread across brain cell types further amplifying of NF-κB transcription through loops involving cytokines, chemokines, oxidases and proteases. Evidence supports the spread and persistence of brain innate immune gene induction as creating the neurobiology of addiction. Human studies of genetic risk for alcoholism and post-mortem brain support the role of innate immune genes in addiction. Animal behavior studies indicate increasing drug consumption and mounting negative affect and depression-like behavior are due to innate immune gene induction. Further, frontal cortical hyperexcitability, behavioral flexibility and loss of behavioral control can all be linked to innate immune genes. Together these finding suggest the neurobiology of addiction is due to innate immune gene altered signaling inducing the behaviors that define addiction. Therapies that blunt brain innate immune gene induction may represent new and novel approaches to preventing and/or reversing addiction.
The Authors wish to acknowledge Diana Lotito for help with the preparation of the manuscript as well as support from the Bowles Center for Alcohol Studies, School of Medicine University of North Carolina and the National Institutes of Health, National Institute on Alcoholism and Alcohol Abuse, AA020023, AA020024, AA020022, AA019767, AA11605.
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.